Table 1 A summary of clinical trials (Phases 2, 3, and 4) based on the human epidermal growth factor receptor 2 (HER2)-targeted therapies using specific anti-bodies in HER2 positive tumor cells registered in ClinicalTrails.gov (September 2021)
Condition | Drug | Study phase | Status | Participant number | Location | NCT number |
|---|---|---|---|---|---|---|
Advanced Breast Cancer | GB221 | 3 | Recruiting | 338 | China | NCT04164615 |
Advanced Breast Cancer | Trastuzumab | 2 | Recruiting | 16 | USA | NCT04329065 |
Breast Cancer | Trastuzumab | 2 | Not yet recruiting | 59 | China | NCT04034823 |
Breast Cancer | Bevacizumab | 2 | Completed | 50 | USA | NCT00095706 |
Breast Cancer Gastric Cancer Gastroesophageal Junction Cancer | ZW25 | 2 | Recruiting | 50 | China S. Korea Taiwan | NCT04276493 |
Breast Cancer | GB221 | 2 | Recruiting | 132 | China | NCT04170595 |
Breast Cancer | RC48-ADC | 2/3 | Recruiting | 301 | China | NCT03500380 |
Breast Cancer | Trastuzumab | 2 | Completed | 55 | USA | NCT00019812 |
Colorectal Cancer | Trastuzumab | 2 | Completed | 32 | USA | NCT00003995 |
Urothelial Carcinoma Advanced Cancer | RC48-ADC | 2 | Completed | 43 | China | NCT03507166 |
Advanced Solid Tumors | Ertumaxomab | 2 | Terminated | 14 | Germany | NCT01569412 |
Breast Cancer | Trastuzumab | 2 | Completed | 50 | USA | NCT00003539 |
Endometrial Cancer | SYD985 | 2 | Recruiting | 60 | International | NCT04205630 |
Gastric Cancer | Trastuzumab | 2 | Recruiting | 52 | China | NCT04661150 |
Breast Cancer | Trastuzumab | 2 | Completed | 37 | USA | NCT00006228 |
Breast Cancer | Trastuzumab | 2 | Completed | 200 | USA | NCT00003992 |
Breast Cancer | Trastuzumab | 2 | Recruiting | 90 | France | NCT03571633 |
Non-small-cell lung carcinoma (NSCLC) | Zenocutuzumab | 2 | Recruiting | 250 | International | NCT02912949 |
Breast Cancer | Pertuzumab | 2 | Completed | 70 | International | NCT02491892 |
Gastric Cancer | HLX22 | 2 | Not yet recruiting | 150 | China | NCT04908813 |
Breast Cancer | Pertuzumab Trastuzumab | 2 | Completed | 37 | USA | NCT00301899 |
Breast Cancer | MRG002 | 2 | Recruiting | 60 | China | NCT04924699 |
Urothelial Carcinoma | MRG002 | 2 | Recruiting | 58 | China | NCT04839510 |
Metastatic Biliary Tract Cancer | MRG002 | 2 | Recruiting | 86 | China | NCT04837508 |
Biliary Tract Cancers | ZW25 | 2 | Recruiting | 100 | USA | NCT04466891 |
Gastrointestinal Cancer | ZW25 | 2 | Recruiting | 362 | USA Canada S. Korea | NCT03929666 |
Breast Cancer | ARX788 | 2 | Recruiting | 200 | USA Australia | NCT04829604 |
Colorectal Neoplasm | DS-8201a | 2 | Completed | 70 | International | NCT03384940 |
Advanced Solid Tumors | MRG002 | 2 | Recruiting | 152 | China | NCT04492488 |